R
Rita Berardelli
Researcher at University of Turin
Publications - 27
Citations - 861
Rita Berardelli is an academic researcher from University of Turin. The author has contributed to research in topics: Mineralocorticoid & Addison's disease. The author has an hindex of 14, co-authored 27 publications receiving 777 citations.
Papers
More filters
Journal ArticleDOI
Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission.
Roberta Giordano,Andreea Picu,Elisa Marinazzo,Valentina D’Angelo,Rita Berardelli,Ioannis Karamouzis,D. Forno,Domenico Zinnà,Mauro Maccario,Ezio Ghigo,Emanuela Arvat +10 more
TL;DR: Cushing’s syndrome is associated with several comorbidities responsible for the increased cardiovascular risk, not only during the active phase but also after disease remission.
Journal ArticleDOI
Neuroregulation of the hypothalamus-pituitary-adrenal (HPA) axis in humans: effects of GABA-, mineralocorticoid-, and GH-Secretagogue-receptor modulation.
Roberta Giordano,Micaela Pellegrino,Andreea Picu,Lorenza Bonelli,Marcella Balbo,Rita Berardelli,Fabio Lanfranco,Ezio Ghigo,Emanuela Arvat +8 more
TL;DR: GABA agonists (mainly ALP), ghrelin, as well as MR agonists/antagonists, may represent good tools to explore the activity of the HPA axis in both physiological conditions and pathological states characterized by an impaired control of the corticotroph function.
Journal ArticleDOI
Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas.
Roberta Giordano,Elisa Marinazzo,Rita Berardelli,Andreea Picu,Mauro Maccario,Ezio Ghigo,Emanuela Arvat +6 more
TL;DR: The risk of mass enlargement, hormonal, and metabolic impairment over time is globally low, and Conservative management seems to be appropriate in adrenal incidentalomas, but further prospective studies are needed to establish the long-term outcome of such patients.
Journal ArticleDOI
Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison’s disease
Roberta Giordano,Federica Guaraldi,Elisa Marinazzo,Federica Fumarola,Alessia Rampino,Rita Berardelli,Ioannis Karamouzis,Manuela Lucchiari,Tilde Manetta,Giulio Mengozzi,Emanuela Arvat,Ezio Ghigo +11 more
TL;DR: In AD patients, PLEN reduces central adiposity, and improves glucose and metabolism parameters and health-related quality of life (HRQoL), using 30-Addi QoL questionnaire, were evaluated.
Journal ArticleDOI
Metabolic and cardiovascular profile in patients with Addison's disease under conventional glucocorticoid replacement.
Roberta Giordano,Stefania Marzotti,M. Balbo,S. Romagnoli,Elisa Marinazzo,Rita Berardelli,Giuseppe Migliaretti,Andrea Benso,Alberto Falorni,Ezio Ghigo,Emanuela Arvat +10 more
TL;DR: A higher prevalence of central adiposity, impaired glucose tolerance and dyslipidemia in AD patients is shown and no significant correlation was found between the above mentioned metabolic parameters and either hormone levels or disease duration.